TY - JOUR
T1 - Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month
AU - Martín-Ventura, Jose Luis
AU - Blanco-Colio, Luis Miguel
AU - Gómez-Hernández, Almudena
AU - Muñoz-García, Begoña
AU - Vega, Melina
AU - Serrano, Javier
AU - Ortega, Luis
AU - Hernández, Gonzalo
AU - Tuñón, José
AU - Egido, Jesús
PY - 2005/8
Y1 - 2005/8
N2 - Background and Purpose - To investigate the effect of short-term high-dose atorvastatin on blood and plaque inflammation in patients with carotid stenosis. Methods - Twenty patients undergoing carotid endarterectomy without previous statin treatment were randomized to receive either atorvastatin 80 mg/d (n = 11) or no statins (n = 9) for 1 month. We studied inflammatory mediators in plasma (enzyme-linked immunosorbent assay), peripheral blood mononuclear cells (PBMCs; quantitative RT-PCR and EMSA) and plaques (immunohistochemistry and Southwestern histochemistry). Results -Atorvastatin significantly decreased total and low-density lipoprotein cholesterol and prostaglandin E2 plasma levels. PBMCs from treated patients showed impaired NF-κB, activation and MCP-1 and COX-2 mRNA expression. Carotid atherosclerotic plaques demonstrated a significant reduction in macrophage infiltration, activated NF-κB, and COX-2 and MCP-1 expression. Conclusions - Intensive treatment with atorvastatin decreases inflammatory activity of PBMCs and carotid atherosclerotic plaques in I month. These data strongly suggest that the antiinflammatory effect of high doses of statins in humans can be seen very early.
AB - Background and Purpose - To investigate the effect of short-term high-dose atorvastatin on blood and plaque inflammation in patients with carotid stenosis. Methods - Twenty patients undergoing carotid endarterectomy without previous statin treatment were randomized to receive either atorvastatin 80 mg/d (n = 11) or no statins (n = 9) for 1 month. We studied inflammatory mediators in plasma (enzyme-linked immunosorbent assay), peripheral blood mononuclear cells (PBMCs; quantitative RT-PCR and EMSA) and plaques (immunohistochemistry and Southwestern histochemistry). Results -Atorvastatin significantly decreased total and low-density lipoprotein cholesterol and prostaglandin E2 plasma levels. PBMCs from treated patients showed impaired NF-κB, activation and MCP-1 and COX-2 mRNA expression. Carotid atherosclerotic plaques demonstrated a significant reduction in macrophage infiltration, activated NF-κB, and COX-2 and MCP-1 expression. Conclusions - Intensive treatment with atorvastatin decreases inflammatory activity of PBMCs and carotid atherosclerotic plaques in I month. These data strongly suggest that the antiinflammatory effect of high doses of statins in humans can be seen very early.
KW - Atherosclerosis
KW - Blood
KW - Carotid arteries
KW - Inflammation
UR - https://www.scopus.com/pages/publications/23244447710
U2 - 10.1161/01.STR.0000174289.34110.b0
DO - 10.1161/01.STR.0000174289.34110.b0
M3 - Article
C2 - 16020773
AN - SCOPUS:23244447710
SN - 0039-2499
VL - 36
SP - 1796
EP - 1800
JO - Stroke
JF - Stroke
IS - 8
ER -